14.96
3.86%
-0.60
After Hours:
14.96
Denali Therapeutics Inc stock is currently priced at $14.96, with a 24-hour trading volume of 1.12M.
It has seen a -3.86% decreased in the last 24 hours and a -24.71% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $15.78 pivot point. If it approaches the $14.95 support level, significant changes may occur.
Previous Close:
$15.56
Open:
$15.25
24h Volume:
1.12M
Market Cap:
$2.13B
Revenue:
$340.81M
Net Income/Loss:
$-145.22M
P/E Ratio:
-13.72
EPS:
-1.09
Net Cash Flow:
$-370.93M
1W Performance:
-9.88%
1M Performance:
-24.71%
6M Performance:
-23.83%
1Y Performance:
-37.38%
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
650-866-8548
Address
151 Oyster Point Boulevard, 2nd Floor, South San Francisco
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-13-23 | Initiated | Citigroup | Buy |
Nov-20-23 | Resumed | JP Morgan | Overweight |
Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
Sep-06-23 | Initiated | B. Riley Securities | Buy |
Jan-30-23 | Initiated | SVB Securities | Outperform |
Dec-05-22 | Initiated | Cowen | Outperform |
Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
Nov-02-22 | Initiated | BofA Securities | Buy |
Jun-23-22 | Initiated | Berenberg | Buy |
Dec-10-21 | Resumed | Raymond James | Mkt Perform |
Sep-21-21 | Initiated | Oppenheimer | Outperform |
Sep-01-21 | Initiated | SMBC Nikko | Outperform |
May-18-21 | Initiated | UBS | Buy |
Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
Sep-14-20 | Resumed | JP Morgan | Overweight |
Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
Feb-24-20 | Initiated | Jefferies | Buy |
Feb-19-20 | Initiated | Stifel | Hold |
Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
Sep-26-19 | Initiated | Wedbush | Neutral |
Sep-13-19 | Initiated | Nomura | Buy |
Aug-09-19 | Initiated | BTIG Research | Buy |
Jun-26-19 | Initiated | H.C. Wainwright | Buy |
Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
Nov-12-18 | Initiated | Janney | Buy |
Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
Jan-02-18 | Initiated | Evercore ISI | Outperform |
Jan-02-18 | Initiated | Goldman | Neutral |
Jan-02-18 | Initiated | JP Morgan | Overweight |
Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Why Denali Therapeutics (DNLI) Stock Might be a Great Pick
Zacks Investment Research
Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
Zacks Investment Research
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
Zacks Investment Research
Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know
Benzinga
4 Analysts Assess Denali Therapeutics: What You Need To Know
Benzinga
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
Zacks Investment Research
Denali Therapeutics Inc Stock (DNLI) Financials Data
Denali Therapeutics Inc (DNLI) Revenue 2024
DNLI reported a revenue (TTM) of $340.81 million for the quarter ending September 30, 2023, a +207.89% rise year-over-year.
Denali Therapeutics Inc (DNLI) Net Income 2024
DNLI net income (TTM) was -$145.22 million for the quarter ending December 31, 2023, a +55.45% increase year-over-year.
Denali Therapeutics Inc (DNLI) Cash Flow 2024
DNLI recorded a free cash flow (TTM) of -$370.93 million for the quarter ending December 31, 2023, a -41.28% decrease year-over-year.
Denali Therapeutics Inc (DNLI) Earnings per Share 2024
DNLI earnings per share (TTM) was -$1.08 for the quarter ending December 31, 2023, a +58.46% growth year-over-year.
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1 clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program that targets aSyn, a protein that has been identified as genetically linked to Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: beta-secretase 1/Tau, a bispecific program targeting the production of amyloid beta and the spreading of Tau. Further, it is developing LF1, a protein to treat neurodegeneration; and DNL788, a small molecule product candidate for the treatment of Alzheimer's disease and ALS. Additionally, the company has various seed program, which are under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, and AbCellera Biologics. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Cap:
|
Volume (24h):